The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A multicenter, randomized, double-blind, six-month maintenance study to compare the efficacy, safety, and tolerability of H 199/18 40 mg, H 199/18 20 mg, and H 199/18 10 mg with placebo in healed erosive esophagitis subjects.
- collapse A multicenter, randomized, double-blind, eight week comparative efficacy and safety study of H 199/18 20 mg, H 199/18 40 mg and omeprazole 20 mg in study subjects with erosive esophagitis
- collapse A placebo-controlled study on the efficacy of on demand treatment with H 199/18 40 mg in maintaining control of symptoms in patients with gastroesophageal reflux disease without macroscopic esophagitis - A multicentre study
- collapse An efficacy and safety study of H 199/18 40 mg vs. omeprazole in the management of patients with gastroesophageal reflux symptoms without macroscopic esophagitis - A multicentre study
- collapse A placebo-controlled study on the efficacy of on demand treatment with two doses of H 199/18 in maintaining control of symptoms in patients with gastroesophageal reflux disease without macroscopic esophagitis - A multicentre study
- collapse A dose-finding/efficacy and safety study of H 199/18 vs. omeprazole management of patients with gastroesophageal reflux symptoms without macroscopic esophagitis - A multicenter study
- collapse Comparative study on 20 and 40 mg H 199/18 and 20 mg omeprazole with regard to effect on 24-hour intragastric pH
- collapse Pharmacokinetics of quinidine with and without co-administration of H 199/18 sodium in healthy volunteers
- collapse The aim of the study was to investigate the pharmacokinetics of diazepam and the formation of one of its active metabolites, N-desmethyldiazepam, after a single i.v. dose, during repeated oral administration of H 199/18 or placebo in healthy subjects.
- collapse An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 20 mg Esomeprazole Administered Orally and Intravenously as a 15 minute infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects with Symptoms of Gastroesophageal Reflux Disease (GERD
